Fidia S.p.A.

BIT:FDA Stock Report

Market Cap: €1.6m

Fidia Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Fidia.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Machinery earnings growth26.9%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

Recent updates

Investors Give Fidia S.p.A. (BIT:FDA) Shares A 34% Hiding

Oct 18
Investors Give Fidia S.p.A. (BIT:FDA) Shares A 34% Hiding

It's Down 40% But Fidia S.p.A. (BIT:FDA) Could Be Riskier Than It Looks

Aug 29
It's Down 40% But Fidia S.p.A. (BIT:FDA) Could Be Riskier Than It Looks

Further Upside For Fidia S.p.A. (BIT:FDA) Shares Could Introduce Price Risks After 28% Bounce

Jun 20
Further Upside For Fidia S.p.A. (BIT:FDA) Shares Could Introduce Price Risks After 28% Bounce

Estimating The Fair Value Of Fidia S.p.A. (BIT:FDA)

May 28
Estimating The Fair Value Of Fidia S.p.A. (BIT:FDA)

Risks Still Elevated At These Prices As Fidia S.p.A. (BIT:FDA) Shares Dive 31%

Feb 13
Risks Still Elevated At These Prices As Fidia S.p.A. (BIT:FDA) Shares Dive 31%

Is Fidia (BIT:FDA) A Risky Investment?

Dec 23
Is Fidia (BIT:FDA) A Risky Investment?

Fidia S.p.A.'s (BIT:FDA) Business Is Trailing The Industry But Its Shares Aren't

Oct 04
Fidia S.p.A.'s (BIT:FDA) Business Is Trailing The Industry But Its Shares Aren't

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Fidia has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

BIT:FDA - Analysts future estimates and past financials data (EUR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
6/30/202429-6-15-14N/A
3/31/202429-4-10-9N/A
12/31/202329-1-5-5N/A
9/30/202326-3-10N/A
6/30/202324-533N/A
3/31/202324122N/A
12/31/202225601N/A
12/31/202124-301N/A
12/31/202022-634N/A
6/30/202038-445N/A
3/31/202043-456N/A
12/31/201946-423N/A
9/30/201957-202N/A
6/30/201955-3-6-4N/A
3/31/201961-1-7-5N/A
12/31/201859-1-5-4N/A
9/30/201849-4-10N/A
6/30/201854-323N/A
3/31/201847-4N/A2N/A
12/31/201747-3N/A6N/A
9/30/201751-1N/A2N/A
6/30/201750-1N/A2N/A
3/31/2017591N/A-3N/A
12/31/2016592N/A-6N/A
9/30/2016582N/A-2N/A
6/30/2016593N/A-2N/A
3/31/2016634N/A9N/A
12/31/2015613N/A5N/A
9/30/2015635N/A5N/A
6/30/2015655N/A5N/A
3/31/2015552N/A2N/A
12/31/2014553N/A5N/A
9/30/2014490N/A-1N/A
6/30/201444-1N/A0N/A
3/31/2014480N/A3N/A
12/31/201345-1N/A3N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if FDA's forecast earnings growth is above the savings rate (2.5%).

Earnings vs Market: Insufficient data to determine if FDA's earnings are forecast to grow faster than the Italian market

High Growth Earnings: Insufficient data to determine if FDA's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if FDA's revenue is forecast to grow faster than the Italian market.

High Growth Revenue: Insufficient data to determine if FDA's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if FDA's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y